NYSE:CBM Cambrex (CBM) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free CBM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$59.99▼$59.9950-Day Range$59.99▼$59.9952-Week Range$33.80▼$60.29VolumeN/AAverage Volume218,726 shsMarket Capitalization$2.02 billionP/E Ratio21.66Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cambrex alerts: Email Address Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Cambrex Stock (NYSE:CBM)Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Read More Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. CBM Stock News HeadlinesMarch 27, 2024 | tmcnet.comOne Equity Partners Invests in Italian Agricultural Tractor Attachment Manufacturer CBMMarch 19, 2024 | morningstar.comChina CBM Group Co Ltd 08270November 2, 2023 | finance.yahoo.comCambrex Announces Sale of Drug Product Business UnitOctober 29, 2023 | investing.comCBM_old Historical DataOctober 24, 2023 | finance.yahoo.comSnapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API DevelopmentOctober 18, 2023 | stockhouse.comSK pharmteco to showcase its extensive APIs and CGT capabilities in CPHI 2023September 21, 2023 | businesswire.comSK pharmteco to Expand Capabilities with Acquisition of Controlling Interest in Center for Breakthrough MedicinesSeptember 7, 2023 | finance.yahoo.comCleantech Building Materials: Result of General MeetingAugust 29, 2023 | markets.businessinsider.comDIVERGENT Energy Services Announces the Release of 2023 Second Quarter ResultsAugust 14, 2023 | finance.yahoo.comCleantech Building Materials: Notice of General MeetingMay 31, 2023 | markets.businessinsider.comCambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial AgreementMay 30, 2023 | juniorminingnetwork.comCollective Mining Drills 162.20 Metres at 3.90 g/t Gold Equivalent From Surface at the...January 18, 2023 | prnewswire.comCambrex fait l'acquisition de Snapdragon Chemistry, un leader dans les services de développement d'IPA à flux continuDecember 24, 2022 | msn.comRepair works at LRT, MRT, Monorail stations to be completed by FebruaryOctober 14, 2022 | businesswire.comVitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2028 - ResearchAndMarkets.com - Business WireOctober 9, 2022 | benzinga.comWith 5.0% CAGR, Small Molecule API Market Size Worth US$ 300.2 Billion by 2030 | Research for Developing - BenzingaOctober 5, 2022 | markets.businessinsider.comCambrex Announces Stability Storage Expansions in Ireland and BelgiumOctober 4, 2022 | prnewswire.comCambrex Announces Stability Storage Expansions in Ireland and Belgium - PR NewswireSeptember 28, 2022 | streetinsider.comMedicx Health Appoints Theresa Greco as President and Stacey Levas as Senior Vice President of Marketing - StreetInsider.comSeptember 27, 2022 | prnewswire.comInvestigational New Drug CDMO Market worth $7.47 billion by 2030 - Exclusive Report by InsightAce Analytic - PR NewswireSeptember 20, 2022 | finance.yahoo.comBlockchain Moon Acquisition Corp. appoints John P. Hopkins and Carl J. Johnson as new Independent Directors - Yahoo FinanceSeptember 19, 2022 | msn.comONGC wants government to scrap windfall tax on domestically produced crude oilSeptember 19, 2022 | msn.comONGC wants govt to scrap windfall tax, USD 10 gas priceSeptember 16, 2022 | businesswire.comKimball Electronics, Inc. Announces Appointment of Additional Director - Business WireSeptember 2, 2022 | news.yahoo.comCambrex finishes first phase of expansion - Yahoo NewsSee More Headlines Receive CBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cambrex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/02/2018Today6/11/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical Preparations Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CBM CUSIP13201110 CIK820081 Webwww.cambrex.com Phone201-804-3000FaxN/AEmployees1,732Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$2.77 Trailing P/E Ratio21.66 Forward P/E RatioN/A P/E GrowthN/ANet Income$92.41 million Net Margins5.96% Pretax MarginN/A Return on Equity5.38% Return on Assets2.50% Debt Debt-to-Equity Ratio0.76 Current Ratio2.37 Quick Ratio1.70 Sales & Book Value Annual Sales$532.09 million Price / Sales3.80 Cash Flow$3.91 per share Price / Cash Flow15.36 Book Value$19.48 per share Price / Book3.08Miscellaneous Outstanding Shares33,720,000Free FloatN/AMarket Cap$2.02 billion OptionableOptionable Beta2.14 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Steven M. Klosk (Age 62)Pres, CEO & Director Mr. Gregory P. Sargen (Age 53)Exec. VP of Corp. Devel. & Strategy and CFO Mr. Shawn P. Cavanagh (Age 53)Exec. VP & COO Ms. Samantha M. Hanley (Age 41)VP, Gen. Counsel & Corp. Sec. Mr. James G. Farrell (Age 52)VP & Corp. Controller Key CompetitorsPacific Biosciences of CaliforniaNASDAQ:PACBHarvard BioscienceNASDAQ:HBIOaTyr PharmaNASDAQ:LIFEThermo Fisher ScientificNYSE:TMOAgilent TechnologiesNYSE:AView All Competitors CBM Stock Analysis - Frequently Asked Questions How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) posted its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to analysts' expectations of $132.78 million. Cambrex had a net margin of 5.96% and a trailing twelve-month return on equity of 5.38%. The firm's quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.76 earnings per share. What other stocks do shareholders of Cambrex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Illumina (ILMN), AbbVie (ABBV), NVIDIA (NVDA), CVS Health (CVS), Gilead Sciences (GILD), Intel (INTC), Walt Disney (DIS), Juno Therapeutics (JUNO) and Under Armour (UAA). This page (NYSE:CBM) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cambrex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cambrex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.